XXXX you, Thank and quarter corporate morning, good to fourth earnings update. Claudia, Welcome the and everyone. call
change goal grow Our is global patients' management market to in that with leadership our fluid solutions lives.
the business the have and care. our needs the years, of in past failure in needs patients cardiovascular assets, to acute meeting serving we leveraged steadily chronic human our beyond kidney financial and two pediatric heart core During expanding life-saving surgery needs
new areas characterized experienced by we've two these Happily, chronic focus than quicker failure. sales heart in are much of cycles
demand also increased for this placements, As disposable only lot made console in circuits. for well, but greatly We not our a progress filter of bodes XXXX.
team in our tripled than bottom we from size growth add our cardiovascular organization our specialized the base. of domestic of more new and more and first, growing we years our leverage fall the to enable positioned past categories: made Going we that to exceed important investments into stakeholders. XXXX, are expectations will believe restructured sales firepower clinical segments pediatrics, to serve into three surgery in top to support the our areas us and customer of investments we Those basic meet two during two to
higher, our especially filter gross to which higher margins, with we points XX our to year, climb expect and manufacturing percentage the XXXX than internal significantly Second, disposable we them increase averaged expanded circuits. capacity in previous
fourth and our later our year. which new Claudia CFO, quarter our a we the review In for few I the SmartFlow investments detail. Third, to both discuss more indication, minutes, FDA the will get will new Aquadex market just made Drayton, clearance and in for pediatric financial console results
turning average the for to last several our margin of the and XXXX XXXX, going over investments just increased internally beyond. set that stage a changes XX%, filter that to Aquadex disposable for manufacturing blood more XX% to Significant plus margins anticipate gross By about we we disposable Before circuits. Aquadex our and I'm to led share importantly, design achievements over call on the moving year, FlexFlow of performance detail engineering improved Claudia, the circuits console. and our consoles,
we the we the Aquadex clearance of received and launching process second-generation it internationally. console are the FDA and Mark SmartFlow in in This CE quarter, for U.S. and console, as now the
physicians therapy. introduces that SmartFlow integrated diagnostics guide The new help new
this We enhancements, new to that file the the therapy complete cover we But remember position a which submitted quarter of near will than our originally you up time, a use taking XXX(k) three more label, was in by therapy more pediatric expect us the extra allow to patents to have provide Many with later planned. that for ended some market. in a stronger important of that pediatric to much application Aquadex applied of five puts and we future.
XXX(k) that pediatric we to February we are pleased very patients market above weighing XX. for So on XX clearance received note kilograms and
and the begins this month hospitals implement the pediatric market with children's XX into training contacted seeking that the us first launch Aquadex to and Our servicing purchase therapy.
experienced in of than rates. kilograms X greater XXX to end-stage XX results to Using disease, kilograms of from titled published Kidney Nephrology below clinical American market expectations for high very acute It XX in due classes: patients Ultrafiltration year fluid the kilograms, positive journal an and the last weight of mortality Society injury, in Device. the high kilograms, have clinical Support XX suffering We the overload, pediatric Children kidney XX all on which reported renal
papers of XX, outcome rate; between XX% and of to were n and supports data with Aquadex was kilograms, system. XX Aquadex the XX, a kilograms Patients All those other no XX% the to treated weight the receive of XX survival a patients survived. kilograms, life-saving under n over experienced did patients those system. Aquadex XX% the kilograms across therapy author XX, bring XX not primary children In of of the therapy. the of and under weighing The and three the who opportunity survival to alternative XXX% of statement, end This weighing XX categories had with n survived; of treatment. said, compelling XX therapy, the one weighing
In heart-lung days the machine. shorten reduce It sales to the additional is patients the highest reason for increase from be system intensive of reason physicians cardiac for time and patients ventilator, cardiovascular focus first vital overload to surgery, patients and on treatment the the after XX on ultrafiltration time discharge. surgery medical and manage simple surgical our third after flowing a care growth specialty is hospital overload the hospital to can the the ambulation, method through ICU six to be cardiac readmitted simple of where and this Fluid patient also by opportunity in surgery, extubated post a cardiac is fluid the the properly surgical unit. the put to the a cardiac in from because remove discharge form fluid to that surgical immediately We're market compensate any need fluid the patient to our discharge. for post-surgery excess is controlling liters post to in speed is in predictable days acute readmitted in the the the significant X expanding to Aquadex to the of remove the four needs XX blood Number be the rapidly prescribed
after hospitals excess costs care, advantage. So for also better If in not who operate It only codes. another reimbursement fluid patient shows the surgery costly in but is also volume not penalties. Aquadex quality resolved system could cutting its scores and potential with set cardiac value brings and reimbursement it by event an in without a nephrologists, considered specialist adverse a hit is in result surgery intervention
to much included sales and sales greatly as Commercial I uses domestic and We the support I top-to-bottom is consumable a and circuits my are our much and In XX U.S. of sales Jaramillo generally expanded into filling cycles as of shorter pediatric our cardiovascular now are organization, leading Nestor XX clinical our of complement said, our providing sales our of Officer. higher. full restructuring transition territories. opening leadership where, reps remarks, the filter have have sales organizations. hiring is surgery Chief Nestor Nestor markets, the mentioned that
growth, our increased our use team obtained our hospital who account. opportunities. it specialist of from Mark but in International to professionals each equipment, XX, until talented that take year the also train full four own increased markets important clinical be We we advantage to wasn't utilization to when CE encourage we to not increasingly last Aquadex also consoles could those will our only the of but
Switzerland, Asia. Southeast joining new impetus Greece, in they for And have distributors footprint in announced by Austria Kingdom in India, partners our year, our Much are our Last technology. utilize even This international has have and United patient physicians and added who I and distributors instigated the Italy, current spreading for care. a speak, understanding studying ways Brazil, as year, Germany, a system we the of countries. of passion and Aquadex deep our new more into to expansion been better the long-time we to XX Spain indications
Week the Doctors bridge from we clinical analysis Sinai that efficacy simplicity presentation including Aquadex as the of acute disease, overload. in of end-stage York recently evaluation example, and transplant. cardiogenic Nephrology's of and and patients a at advanced a anasarca, In Society postoperative announced data shock, American fluid with clinical in investigator-initiated settings Mount Kidney in issues New disease overload, treating another in fluid with liver the at initiated liver highlighted care hemodialysis such necrosis have of an FlexFlow Aquadex critical treatment of use renal between ultrafiltration tubular
through will who walk details. results now over to XXXX our will the QX Claudia, call you financial and turn I
I to open provide comments, closing the will that, some call and questions. we'll Following
